eIF-4γ Activators
eIF-4γ Activators are a collection of chemical compounds that enhance the activity of eIF-4γ by influencing key upstream signaling pathways involved in the process of translation initiation. The interaction of these activators with the mTOR pathway, in particular, plays a crucial role in modulating eIF-4γ's function. Rapamycin, Everolimus, and Temsirolimus, as mTOR inhibitors, increase the activity of 4E-BP1, an inhibitor of eIF-4E. This increased 4E-BP1 activity leads to a reduction in eIF-4E's involvement in the eIF-4F complex, indirectly boosting eIF-4γ's role in this complex and thus its function in translation initiation. Moreover, compounds like Resveratrol and Metformin, which impact mTOR and AMPK pathways, respectively, contribute to this regulatory mechanism by similarly enhancing 4E-BP1 activity, resulting in an augmented role for eIF-4γ in the initiation of translation.
In addition, the modulation of the PI3K/Akt/mTOR pathway by chemicals such as Insulin, Wortmannin, LY294002, and Perifosine significantly affects eIF-4γ activity. Insulin, through activation of this pathway, indirectly supports eIF-4γ function by facilitating the formation of the eIF-4F complex, of which eIF-4γ is a component. In contrast, PI3K inhibitors like Wortmannin and LY294002 lead to increased 4E-BP1 activity, thereby indirectly promoting eIF-4γ's involvement in translation initiation through reduced eIF-4E activity. Furthermore, the influence of MEK inhibitors PD 98059 and U0126 on the MAPK/ERK pathway indirectly alters the dynamics of the PI3K/Akt/mTOR pathway, further impacting eIF-4γ's activity. This intricate interplay of signaling pathways and the role of these chemical activators underscore the sophisticated regulation of eIF-4γ in cellular translation, highlighting how upstream signaling modulations can significantly influence the functional activity of key translational proteins like eIF-4γ.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway, which is integral to protein synthesis regulation. This inhibition increases the activity of 4E-BP1, leading to reduced eIF-4E activity. Since eIF-4E is part of the eIF-4F complex, which includes eIF-4γ, the reduced eIF-4E activity indirectly enhances eIF-4γ's role in translation initiation. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin triggers the PI3K/Akt/mTOR pathway, leading to the phosphorylation and inactivation of 4E-BP1. This inactivation releases eIF-4E, facilitating its association with eIF-4γ in the eIF-4F complex, thereby enhancing eIF-4γ's function in initiating translation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, as a PI3K inhibitor, impedes the activation of the Akt/mTOR pathway. This leads to enhanced 4E-BP1 activity, reducing eIF-4E's availability. The reduction in eIF-4E activity indirectly promotes eIF-4γ's involvement in translation initiation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, leading to decreased Akt/mTOR pathway activity and increased 4E-BP1 activity. This enhancement in 4E-BP1 activity indirectly supports eIF-4γ's role in the initiation of translation by modulating eIF-4E activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 inhibits MEK in the MAPK/ERK pathway. By doing so, it indirectly affects the PI3K/Akt/mTOR pathway, reducing 4E-BP1 phosphorylation. This reduction enhances eIF-4γ activity in translation initiation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, a MEK inhibitor, modulates the MAPK/ERK pathway, indirectly affecting the PI3K/Akt/mTOR pathway. The consequent reduction in 4E-BP1 phosphorylation indirectly enhances eIF-4γ's function in translation initiation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol inhibits mTOR, leading to increased 4E-BP1 activity. This enhanced 4E-BP1 activity indirectly augments eIF-4γ's function in translation initiation by modulating eIF-4E activity. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin activates AMP-activated protein kinase (AMPK), which negatively regulates mTOR. This inhibition increases 4E-BP1 activity, indirectly enhancing eIF-4γ's role in the initiation of translation. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, leading to mTOR inhibition and subsequent 4E-BP1 activation. This activation indirectly enhances eIF-4γ's activity in translation initiation by reducing eIF-4E availability. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus, an mTOR inhibitor similar to Rapamycin, increases 4E-BP1 activity, indirectly enhancing eIF-4γ's function in translation initiation by limiting eIF-4E activity. | ||||||